Vor Biopharma/$VOR

1D1W1MYTD1Y5YMAX

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Ticker
$VOR
Sector
Health
Primary listing
NASDAQ
Employees
76
Headquarters
Boston, United States
Website
www.vorbio.com

Vor Biopharma Metrics

BasicAdvanced
$1.1B
0.91
$20.19
1.72
-

Bulls say / Bears say

Telitacicept has a credible efficacy base rather than being an early discovery bet: Vor says its China Phase 3 gMG trial produced statistically significant, clinically meaningful MG-ADL and QMG improvements at week 24, with improvement continuing through week 48. Vor has now completed global UPSTREAM MG enrolment, with topline data due in H1 2027. (GlobeNewswire)
The asset is being built as a multi-indication franchise: telitacicept has secured additional China commercial approvals for Sjögren’s disease and IgA nephropathy, while Vor’s global SjD Phase 3 is on track and a global ocular MG Phase 3 is planned for H1 2027. Success in one indication could therefore support a broader commercial platform rather than a single-label product. (BioSpace, GlobeNewswire)
Near-term financing risk is lower than for many clinical biotechs: Vor reported $466.1m of cash, equivalents and marketable securities at 30 June, plus $48.4m of net July ATM proceeds, and expects this to fund operations into early 2029. That should cover the H1 2027 MG readout and ongoing SjD work without an obvious forced raise before the key catalyst. (BioSpace)
The investment case remains a binary test of whether Chinese efficacy translates to a Western trial. Management said it expects the global effect size to compress, especially because of the placebo arm, so a statistically positive result could still be less differentiated than the China data imply. (StockAnalysis)
Vor is effectively a single-asset clinical-stage company: its value is concentrated in telitacicept, with no established commercial revenue to cushion a failed Phase 3 outcome. The planned ocular MG expansion also adds execution and trial-cost demands before the lead readout. (Simply Wall St)
Even if telitacicept succeeds, the licence economics are heavy: RemeGen can receive up to $330m in regulatory milestones, up to $3.775bn in sales milestones and tiered royalties from high single digits to mid-teens on net sales. Those obligations could reduce the value retained by Vor and make commercial success more expensive to scale. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 19 Sept 2026.

Funds containing Vor Biopharma

AllUSDGBPEUR
Funds
Fund name
Fund size
$VOR weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.07%
iShares Nasdaq US Biotechnology£BTEK
£865M0.07%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.03%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.03%
SPDR MSCI All Country World IM€SPYI
€7.5B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.